<DOC>
	<DOCNO>NCT00144768</DOCNO>
	<brief_summary>The purpose study determine whether development antibody laronidase patient MPS I receive Aldurazyme® impairs clearance GAG substrate .</brief_summary>
	<brief_title>A Study Investigating Relationship Between Development Laronidase Antibody Urinary GAG ( Glycosaminoglycan ) Levels Aldurazyme® Treated Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Have document diagnosis MPS I confirm measurable sign symptom deficient αLiduronidase activity ( &lt; 10 % low limit normal ) . For patient receive Aldurazyme therapy prior study entry : Have available baseline data result urinary GAG level IgG antibody titer collect prior patient 's first Aldurazyme infusion . Provide sign , write informed consent prior protocolrelated procedure perform . Consent legally authorize guardian ( ) ( ) require patient 18 year . Have previously receive Aldurazyme without collection baseline sample specify . Have suspect hypersensitivity Aldurazyme know hypersensitivity component infusion solution . Have receive Hematopoietic Stem Cell Transplantation , injection fibroblast therapy , major organ transplant . Are receive chronic immunosuppressant therapy . Have medical condition , serious intercurrent illness , extenuate circumstance may interfere study compliance include prescribed evaluation followup activity . Are pregnant lactate Have receive investigational drug within 30 day prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>